Published in J Nanobiotechnology on August 15, 2008
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) (2014) 1.07
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev (2014) 0.91
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
Particle margination and its implications on intravenous anticancer drug delivery. AAPS PharmSciTech (2014) 0.81
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Adhesion patterns in the microvasculature are dependent on bifurcation angle. Microvasc Res (2015) 0.79
Non-affinity factors modulating vascular targeting of nano- and microcarriers. Adv Drug Deliv Rev (2015) 0.78
Characterization of nanoparticle delivery in microcirculation using a microfluidic device. Microvasc Res (2014) 0.78
Nanoencapsulation of insulin into zirconium phosphate for oral delivery applications. Biomacromolecules (2010) 0.78
Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems. Ther Deliv (2015) 0.76
Direct Tracking of Particles and Quantification of Margination in Blood Flow. Biophys J (2016) 0.75
Direct intercalation of cisplatin into zirconium phosphate nanoplatelets for potential cancer nanotherapy. Nanoscale (2013) 0.75
Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Threshold levels of fluid shear promote leukocyte adhesion through selectins (CD62L,P,E) J Cell Biol (1997) 3.24
The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials (2006) 2.71
A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng (2005) 1.97
Margination of leukocytes in blood flow through small tubes. Microvasc Res (1984) 1.73
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell (2013) 4.99
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol (2005) 2.42
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA (2004) 2.02
Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials. Int J Cardiol (2012) 2.00
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv (2014) 1.97
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats. Circ Res (2002) 1.67
MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res (2011) 1.67
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol (2011) 1.58
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). JACC Cardiovasc Interv (2013) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
Blocking out the real diagnosis. Lancet (2011) 1.43
[Mechanism of troponin and CK-MB release after percutaneous coronary interventions]. Ital Heart J Suppl (2002) 1.39
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res (2006) 1.34
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 1.17
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Transbrachial intraaortic balloon pumping in severe peripheral atherosclerosis. Ann Thorac Surg (2007) 1.10
AKAP121 downregulation impairs protective cAMP signals, promotes mitochondrial dysfunction, and increases oxidative stress. Cardiovasc Res (2010) 1.09
Aspiration thrombectomy: an easily forgiven "latecomer". J Am Coll Cardiol (2014) 1.09
Cells preferentially grow on rough substrates. Biomaterials (2010) 1.08
Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol (2009) 1.08
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Intracoronary versus intravenous abciximab bolus administration. J Am Coll Cardiol (2014) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06